1. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration. Issue 2 (30th November 2020) Authors: Kim, Aryun; Grover, Anita; Hammon, Kevin; de Hart, Greg; Slasor, Peter; Cherukuri, Anu; Ajayi, Temitayo; Jacoby, David; Schulz, Angela; Specchio, Nicola; de Los Reyes, Emily; Gissen, Paul; Henshaw, Joshua W. Journal: Clinical and translational science Issue: Volume 14:Issue 2(2021) Page Start: 635 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease. Issue 5 (2nd June 2021) Authors: Hammon, Kevin; de Hart, Greg; Vuillemenot, Brian R.; Kennedy, Derek; Musson, Don; O'Neill, Charles A.; Katz, Martin L.; Henshaw, Joshua W. Journal: Clinical and translational science Issue: Volume 14:Issue 5(2021) Page Start: 1810 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗